Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Clinical trial NCT07446452 · RECRUITING

Trial details

NCT number: NCT07446452
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-low Breast Cancer

Start date: 2024-01-01
Primary completion: 2026-12-06
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.